{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-008204","form_type":"8-K","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2023-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.351101+00:00","generated_at":"2026-06-08T00:52:56.849541+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PharmaCyte Biotech invests $5M in Femasys, expanding strategy to utilize $74.6M cash","bullets":["PharmaCyte (PMCB) purchases $5M senior unsecured convertible notes from Femasys (FEMY) at 6% interest, maturing in 2 years.","Notes convertible at $1.18/share; warrants to buy up to ~8.5M FEMY shares at $1.18 and $1.475 per share.","Interim CEO Josh Silverman will join Femasys' Board of Directors; collaboration agreement for joint research.","PharmaCyte had $74.6M cash as of July 31, 2023; investment marks first external tech deployment.","Femasys offers women's health products including late-stage FemBloc and FDA-cleared FemaSeed."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-008204","json":"https://secwatch.observer/filing/0001683168-23-008204.json","markdown":"https://secwatch.observer/filing/0001683168-23-008204.md","text":"https://secwatch.observer/filing/0001683168-23-008204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316823008204/0001683168-23-008204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316823008204/pharmacyte_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T00:52:56.849541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0846172a0b98270e2c1e902b4a28e0aad069062c","claim":"PharmaCyte Biotech, Inc. entered into Collaboration Agreement with Femasys Inc. (effective 2023-11-14).","evidence_excerpt":"ith Femasys Inc. (“Femasys”) , pursuant to which it agreed to purchase from Femasys (i) senior unsecured convertible notes (the “Notes”) in an aggregate principal amount of $5,000,000, convertible into shares of Femasys common stock, par value","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316823008204/0001683168-23-008204-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Femasys Inc."},{"label":"Effective","value":"2023-11-14"}],"fact_type":"material_agreement"},{"claim_id":"1c1a79cd96e28f90f109b1f0b2be57e13f7e4601","claim":"PharmaCyte Biotech, Inc. entered into Registration Rights Agreement with Femasys Inc..","evidence_excerpt":"ith Femasys Inc. (“Femasys”) , pursuant to which it agreed to purchase from Femasys (i) senior unsecured convertible notes (the “Notes”) in an aggregate principal amount of $5,000,000, convertible into shares of Femasys common stock, par value","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316823008204/0001683168-23-008204-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Femasys Inc."}],"fact_type":"material_agreement"},{"claim_id":"50d686e488b25836d2d76382dfd7d4d4d73b7f21","claim":"PharmaCyte Biotech, Inc. entered into Purchase Agreement with Femasys Inc. valued at $5,000,000 (effective 2023-11-14).","evidence_excerpt":"On November 14, 2023, PharmaCyte Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Femasys Inc. (“Femasys”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157075/000168316823008204/0001683168-23-008204-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Femasys Inc."},{"label":"Value","value":"$5,000,000"},{"label":"Effective","value":"2023-11-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}